Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10102066 | 0.88 | PTPN1 (0.41) | MAPTRAB9ANPSR1PTPN1ALKBH1 | |
| SCHEMBL10102086 | 0.86 | PTPN1 (0.43) | MAPTRAB9ANPSR1PTPN1ALKBH1 | |
| SCHEMBL10102147 | 0.84 | PTPN1 (0.41) | MAPTRAB9ANPSR1PTPN1ALKBH1 | |
| SCHEMBL20370139 | 0.81 | PTPN1 (0.45) | RAB9APTPN1LMNAHPGDKMT2A | |
| SCHEMBL10102133 | 0.81 | HRH4 (0.46) | MAPTKMT2A | |
| SCHEMBL9279822 | 0.81 | PTPN1 (0.44) | PTPN1LMNAHPGDKMT2AMEN1 | |
| SCHEMBL6125199 | 0.81 | PTPN1 (0.47) | PTPN1LMNAHPGDKMT2AMEN1 | |
| SCHEMBL10101766 | 0.80 | PTPN1 (0.43) | MAPTRAB9ANPSR1PTPN1LMNA | |
| SCHEMBL9283183 | 0.79 | KCNA3 (0.43) | PTPN1LMNAHPGDKMT2AMEN1 | |
| SCHEMBL9282750 | 0.79 | PTPN1 (0.43) | MAPTRAB9APTPN1LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8828988-B2 | 8-AZA tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-8367654-B2 | 8-AZA tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120108569-A1 | 8-AZA Tetracycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108569-A1 | 8-AZA Tetracycline Compounds | TET1, TET3, HDAC8 | MAPT 921/4885RAB9A 682/4885NPSR1 4718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.